Pancreatic Cancer Research

ResearcherUniversity of LouisvilleActive in the last 2 years

Prakash Radhakrishnan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5314-1630; OpenAlex author ID A5025073506; NIH RePORTER profile ID 10215229. Sources: OpenAlex.

Their work

Papers
23 (first author 2, last author 10)
Trials
0
Grants
2
Labs led
2
Collaborators
57
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 5 papers · 2020: 2 papers · 2021: 4 papers, 1 grant · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper, 1 grant

Papers 23

  1. MUC16 drives macrophage-mediated immunosuppression in pancreatic cancer. Last author DOI 10.1016/j.canlet.2026.218927↗
  2. Unraveling the glyco-immunity nexus in pancreatic cancer. Last author DOI 10.1186/s12943-025-02417-4↗
  3. Humanized Anti-MUC16 Antibody-Conjugated Contrast Agents for Magnetic Resonance Imaging of Pancreatic Cancer. Last author DOI 10.3390/cancers17060957↗
  4. Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6. Last author DOI 10.1158/1535-7163.mct-23-0868↗
  5. Mucins as contrast agent targets for fluorescence-guided surgery of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2023.216150↗
  6. ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody. Co-author DOI 10.1158/1078-0432.ccr-21-1798↗
  7. Truncated O-Glycan-Bearing MUC16 Enhances Pancreatic Cancer Cells Aggressiveness via α4β1 Integrin Complexes and FAK Signaling. Last author DOI 10.3390/ijms23105459↗
  8. MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans. Last author DOI 10.1016/j.canlet.2021.01.015↗
  9. Structure activity relationship (SAR) study identifies a quinoxaline urea analog that modulates IKKβ phosphorylation for pancreatic cancer therapy. Co-author DOI 10.1016/j.ejmech.2021.113579↗
  10. Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer. Last author DOI 10.1016/j.ymthe.2020.12.029↗
  11. IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-21-0368↗
  12. Development of a MUC16-Targeted Near-Infrared Fluorescent Antibody Conjugate for Intraoperative Imaging of Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-20-0033↗
  13. Role of Tumor and Stroma-Derived IGF/IGFBPs in Pancreatic Cancer. First author DOI 10.3390/cancers12051228↗
  14. The glycoprotein mucin-1 negatively regulates GalNAc transferase 5 expression in pancreatic cancer. Last author DOI 10.1002/1873-3468.13532↗
  15. Role of keratan sulfate expression in human pancreatic cancer malignancy. Last author DOI 10.1038/s41598-019-46046-6↗
  16. Truncated O-glycans promote epithelial-to-mesenchymal transition and stemness properties of pancreatic cancer cells. Last author DOI 10.1111/jcmm.14572↗
  17. A Polymeric Nanogel-Based Treatment Regimen for Enhanced Efficacy and Sequential Administration of Synergistic Drug Combination in Pancreatic Cancer. Co-author DOI 10.1124/jpet.118.255372↗
  18. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. First author DOI 10.1186/s12943-018-0927-5↗
  19. Amyloid precursor-like protein 2 (APLP2) affects the actin cytoskeleton and increases pancreatic cancer growth and metastasis. Co-author DOI 10.18632/oncotarget.2990↗
  20. Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Co-author DOI 10.1186/2049-3002-2-18↗
  21. Expression of core 3 synthase in human pancreatic cancer cells suppresses tumor growth and metastasis. Co-author DOI 10.1002/ijc.28322↗
  22. MicroRNA-200c modulates the expression of MUC4 and MUC16 by directly targeting their coding sequences in human pancreatic cancer. Co-author DOI 10.1371/journal.pone.0073356↗
  23. MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Co-author DOI 10.1073/pnas.1203339109↗

Grants 2

  1. Targeting Disease Specific Tn Antigen in Pancreatic Cancer R01CA288372↗
  2. MUC16 in Pancreatic Cancer Progression and Metastasis R01CA208108↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Anthony Hollingsworth · 16 shared papers, 2012–2026 · strength 1.93
  2. Richard D Cummings · 1 shared paper, 1 shared grant, 2025–2026 · strength 1.69
  3. Satish Sagar · 10 shared papers, 2019–2026 · strength 1.50
  4. Christabelle Rajesh · 6 shared papers, 2021–2026 · strength 1.37
  5. Thomas C. Caffrey · 10 shared papers, 2012–2025 · strength 1.21
  6. Divya Thomas · 7 shared papers, 2019–2021 · strength 0.99
  7. Paul M. Grandgenett · 7 shared papers, 2013–2024 · strength 0.67
  8. Aaron M. Mohs · 3 shared papers, 2020–2025 · strength 0.55
  9. Surinder K. Batra · 3 shared papers, 2013–2023 · strength 0.27
  10. Jen Jen Yeh · 2 shared papers, 2021–2022 · strength 0.26
  11. Kamiya Mehla · 4 shared papers, 2012–2021 · strength 0.25
  12. Clara S. Mundry · 1 shared paper, 2026 · strength 0.25
  13. Ying Huang · 1 shared paper, 2026 · strength 0.25
  14. Jayasindu Mathiyazhagan · 1 shared paper, 2025 · strength 0.25
  15. Premila Devi Leiphrakpam · 2 shared papers, 2019–2021 · strength 0.23
  16. Michael Bouvet · 1 shared paper, 2023 · strength 0.18
  17. Kathryn M. Muilenburg · 1 shared paper, 2023 · strength 0.18
  18. Mark A. Carlson · 1 shared paper, 2023 · strength 0.18
  19. Eric N. Aguilar · 1 shared paper, 2024 · strength 0.17
  20. Pankaj Kumar Singh · 3 shared papers, 2012–2021 · strength 0.16
  21. Surendra Kumar Shukla · 2 shared papers, 2014–2021 · strength 0.14
  22. Kyle L. McAndrews · 1 shared paper, 2021 · strength 0.13
  23. Sai Kiran Sharma · 1 shared paper, 2022 · strength 0.13
  24. Brian Matthew Zeglis · 1 shared paper, 2022 · strength 0.13
  25. Jason Stuart Lewis · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.